RP-3 by Replimune for Lung Cancer: Likelihood of Approval

RP-3 is under clinical development by Replimune and currently in Phase I for Lung Cancer.

Two OTC CGMs Cleared; USPSTF Draft Recs for Osteoporosis; Generic Ozempic in Testing

Abbott announced FDA clearance of two over the counter (OTC) continuous glucose monitoring (CGM) systems: one for adults with type 2 diabetes not on insulin

June 12, 2024

Air-powered computers can be a more reliable, cost-effective way to help prevent blood clots and strokes

A new, air-powered computer sets off alarms when certain medical devices fail. The invention is a more reliable and lower-cost way to help prevent blood

August 14, 2024

Early data from rare-disease trial put spotlight on Moderna’s efforts to turn mRNA into medicines

LONDON — Moderna may be best known for its Covid-19 vaccine, but since its start, it’s always been set on developing therapies. It’s run into

April 3, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.